U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07357649) titled 'Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis' on Jan. 12.
Brief Summary: This prospective interventional study aims to evaluate the effects of baricitinib on disease activity, lipid profile, atherogenic index, and procoagulant biomarkers including monocyte-derived human tissue factor and D-dimer in patients with rheumatoid arthritis, compared with conventional therapy.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Rheumatoid Arthritis
Intervention:
DRUG: Baricitinib
Oral baricitinib administered in combination with methotrexate according to standard clinical practice
Recruitment Stat...